Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MRK

Merck & Co Inc

Feb 13 • 04:00PM ET

121.41

+2.17 1.82 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Feb 13, 8:05 AMMerck shares rise after Deutsche Bank upgrades the stock to Buy from Hold and lifts its price target to $150 from $115, citing an undervalued post-Keytruda earnings outlook.

Peers: PFE AZN-D NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO IVV SPY SCHD VTV XLV VIG VYM DGRO

Index	DJIA, S&P 500	P/E	16.69	EPS (ttm)	7.28	Insider Own	0.12%	Shs Outstand	2.48B	Perf Week	-0.43%
Market Cap	301.34B	Forward P/E	12.47	EPS next Y	9.74	Insider Trans	-10.68%	Shs Float	2.48B	Perf Month	9.37%
Enterprise Value	324.52B	PEG	2.09	EPS next Q	-1.51	Inst Own	78.96%	Short Float	1.16%	Perf Quarter	32.76%
Income	18.25B	P/S	4.64	EPS this Y	-42.55%	Inst Trans	-0.79%	Short Ratio	1.95	Perf Half Y	46.70%
Sales	65.00B	P/B	5.82	EPS next Y	88.69%	ROA	15.41%	Short Interest	28.73M	Perf YTD	15.34%
Book/sh	20.85	P/C	16.51	EPS next 5Y	5.98%	ROE	39.51%	52W High	122.66 -1.02%	Perf Year	43.82%
Cash/sh	7.35	P/FCF	23.09	EPS past 3/5Y	8.43% 21.23%	ROIC	19.88%	52W Low	73.31 65.61%	Perf 3Y	10.83%
Dividend Est.	3.23 (2.66%)	EV/EBITDA	10.87	Sales past 3/5Y	3.60% 9.37%	Gross Margin	81.50%	Volatility	2.69% 2.68%	Perf 5Y	69.77%
Dividend TTM	3.28 (2.70%)	EV/Sales	4.99	EPS Y/Y TTM	58.02%	Oper. Margin	41.18%	ATR (14)	3.20	Perf 10Y	159.69%
Dividend Ex-Date	Mar 16, 2026	Quick Ratio	1.44	Sales Y/Y TTM	1.61%	Profit Margin	28.08%	RSI (14)	69.44	Recom	1.90
Dividend Gr. 3/5Y	5.42% 5.75%	Current Ratio	1.66	EPS Q/Q	-19.28%	SMA20	6.90%	Beta	0.28	Target Price	125.35
Payout	45.05%	Debt/Eq	0.80	Sales Q/Q	7.24%	SMA50	12.42%	Rel Volume	0.68	Prev Close	119.24
Employees	75000	LT Debt/Eq	0.77	Earnings	Feb 03 BMO	SMA200	35.25%	Avg Volume	14.75M	Price	121.41
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.43% 1.24%	Trades		Volume	10,099,368	Change	1.82%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-26	Upgrade	Deutsche Bank	Hold → Buy	$150
Jan-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$135
Dec-18-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$130
Nov-24-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$125
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$105
Oct-13-25	Resumed	Citigroup	Neutral	$95
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$90
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135

Show Previous Ratings

Feb-14-26 03:02PM	Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit (MarketBeat)
Feb-13-26 11:38AM	Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates (Zacks)
10:49AM	MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell? (Zacks)
09:57AM	Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA and KEYTRUDA QLEX Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+ (Insider Monkey)
09:36AM	Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? (Zacks)
09:30AM	Loading…
09:30AM	Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:49AM	Stock Market Today: Dow Falls On Surprise CPI Inflation Report; DraftKings Plunges On Earnings (Live Coverage) (Investor's Business Daily)
08:00AM	Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent (Investing.com)
01:09AM	Organon & Co. Q4 Earnings Call Highlights (MarketBeat)
Feb-12-26 03:30PM	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant (Reuters Videos)
06:45AM	Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium (Business Wire)
06:27AM	Sanofi replaces chief Paul Hudson with Merck executive after R&D woes (Financial Times)
Feb-11-26 10:26AM	Merck's Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients (Benzinga)
09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
08:09AM	Loading…
08:09AM	Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? (Zacks)
06:45AM	KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS 1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment (Business Wire)
05:48AM	Merck and Calla Lily partner to advance Callavid platform (Medical Device Network)
Feb-10-26 11:10AM	LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal (Zacks)
11:06AM	Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line? (Zacks)
09:42AM	AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook (Zacks)
12:36AM	5 Revealing Analyst Questions From Merck's Q4 Earnings Call (StockStory)
Feb-09-26 04:42PM	Stock Market Today: Dow Up As Oracle Soars; Cathie Wood Buys Buffett Stock Amid 145% Run (Live Coverage) (Investor's Business Daily)
03:13PM	Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion (Barrons.com)
02:13PM	Stock Market Today: Dow Firm As Oracle Soars On This; Hims & Hers Shares Crater On Novo Move (Live Coverage) (Investor's Business Daily)
11:06AM	Stock Market Today: Dow Gains As Nvidia Jumps; Apple Lags, Energy Stock Tests Entry (Live Coverage) (Investor's Business Daily)
10:29AM	BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? (Zacks)
10:18AM	Stock Market Today: Dow Skids Even As Nvidia Jumps; Monday Plunges, Biopharma Funds Lag (Live Coverage) (Investor's Business Daily)
10:00AM	Eli Lilly Stock Rises. Its Acquiring This Cell Therapy Company for $2.4 Billion. (Barrons.com)
09:55AM	Dow Jones retreat from highs as Amazon and Apple fall (Proactive)
07:51AM	Loading…
07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-07-26 11:50AM	Merck & Co., Inc. (MRK): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:15PM	The Dow Industrials Have Tilted More Toward Financials (The Wall Street Journal)
12:53PM	Big-Name Earnings, Selloffs Highlight Busy Week on Wall Street (Schaeffer's Research)
11:06AM	Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push (Zacks)
11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
09:28AM	Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic (Zacks)
07:08AM	White Houses online service for drug sales debuts with limited impact on prices (BioPharma Dive)
Feb-05-26 02:38PM	Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress (Insider Monkey)
01:21PM	Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (Reuters)
09:15AM	Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
05:44AM	J.P. Morgan Healthcare Conference 2026 Report (Pharmaceutical Technology)
03:00AM	Big Pharma CEOs set sights on massive growth in years to come (Pharma Voice)
Feb-04-26 03:18PM	Jim Cramer on Merck & Co.: "This Is One of My Favorite Pharmaceutical Stocks" (Insider Monkey)
12:16PM	S&P 500 Slips, Nasdaq Drops as Traders Dump Chips (Schaeffer's Research)
10:16AM	Stock Market Today: Dow Rises But Nasdaq Lags On Surprise Jobs Data; Eli Lilly Soars (Live Coverage) (Investor's Business Daily)
01:08AM	Merck & Co., Inc. Q4 Earnings Call Highlights (MarketBeat)
12:35AM	MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance (StockStory)
Feb-03-26 04:26PM	Stocks Tumble on AI Disruption Fears (Barchart)
04:02PM	Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Growth Amidst Challenges (GuruFocus.com)
03:42PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
02:56PM	Pfizer Stock Falls After Solid Earnings. Whats Troubling Wall Street. (Barrons.com)
02:46PM	These Stocks Are Todays Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More (Barrons.com)
02:43PM	Merck Stock Gains as Earnings Top Estimates. Momentum Is Building, Says CEO. (Barrons.com)
12:40PM	MSDs 2026 sales forecast falls short amid patent losses despite strong Q4 (Pharmaceutical Technology)
12:30PM	Dow Hits Record, Nasdaq Sinks as Tech Stocks Retreat (GuruFocus.com)
12:18PM	Merck 2026 Outlook Misses as Gardasil Sales Drop 35% (GuruFocus.com)
12:15PM	Dow's Early Record Fades as Tech Turns South (Schaeffer's Research)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
11:06AM	Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow (Benzinga)
11:04AM	2 Pharma Stocks React to Quarterly Results, Guidance (Schaeffer's Research)
11:00AM	Merck (MRK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
11:00AM	Market Awaits JOLTS Jobs Report (Zacks)
10:26AM	Q4 Earnings, JOLTS & a Changing of the Disney Guard (Zacks)
10:17AM	Stock Market Today: Dow Inches Higher As Palantir Rallies; Rambus Tumbles (Live Coverage) (Investor's Business Daily)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
08:19AM	Pharma stocks slump as Pfizer and Merck report earnings (Quartz)
08:19AM	Merck and Pfizer decline vs the broader market as results released (Quartz)
07:40AM	Merck (MRK) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:24AM	Jim Cramer on Merck & Co.: "I Think It Can Spread Out the Wealth" (Insider Monkey)
07:11AM	Merck shares fall as 2026 guidance disappoints despite solid Q4 results (Investing.com)
06:55AM	Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year (MarketWatch)
06:48AM	Merck's (NYSE:MRK) Q4 CY2025 Sales Beat Estimates (StockStory)
06:48AM	Merck Earnings Top Estimates. Why the Stock Is Falling. (Barrons.com)
06:40AM	Merck: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline (Business Wire)
05:00AM	Advanced Micro Devices heads earnings slate (MarketWatch)
04:34AM	Where is Merck & Co. (MRK) Headed According to Wall Street? (Insider Monkey)
04:19AM	Stock Market Today: S&P 500 eyes fresh record as Dow and Nasdaq also called higher; Palantir rises after earnings; gold and silver rebound; AMD results on tap. (MarketWatch)
03:39AM	Stocks to Watch Tuesday: Palantir, Teradyne, AMD (The Wall Street Journal)
03:01AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-02-26 07:00PM	AMD earnings, Netflix-Warner Bros. hearing: What to Watch (Yahoo Finance Video)
06:02PM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
05:46PM	Market Indexes Bounce Back to Start a New Trading Week (Zacks)
11:40AM	Merck Reports Earnings Tuesday Morning After Gaining 13% Over the Past Year (24/7 Wall St.)
11:12AM	Market Awaits January Manufacturing Numbers (Zacks)
10:35AM	Six More Weeks of Q4 Earnings Season? (Zacks)
10:25AM	What's in Store for These 5 Pharma Bigwigs This Earnings Season? (Zacks)
08:29AM	Palantir, AMD, Amazon and More Stocks with Earnings This Week (Benzinga)
07:00AM	Option Volatility And Earnings Report For February 2 - 6 (Barchart)
02:13AM	Jobs Report, Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
Feb-01-26 10:04PM	Merck (MRK) Q4 Earnings Report Preview: What To Look For (StockStory)
07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 12:35PM	Merck & Co., Inc. (MRK) Joins BofA's "US 1 List" (Insider Monkey)
Jan-30-26 05:45PM	Merck (MRK) Advances While Market Declines: Some Information for Investors (Zacks)
04:57PM	Jobs Report, More Tech Earnings: What to Watch Next Week (The Wall Street Journal)
12:36PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
09:41AM	Merck & Co. Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	Chief Marketing Officer	Feb 12 '26	Sale	121.46	10,000	1,214,562	60,615	Feb 12 04:02 PM
DEAN LI	Officer	Feb 10 '26	Proposed Sale	117.52	10,235	1,202,844		Feb 10 04:38 PM
Li Dean Y	Executive VP & President, MRL	Feb 10 '26	Sale	117.52	10,235	1,202,844	92,035	Feb 10 04:04 PM
JENNIFER ZACHARY	Officer	Feb 09 '26	Proposed Sale	119.15	121,573	14,485,690		Feb 09 04:57 PM
CHIRFI GUINDO	Officer	Feb 09 '26	Proposed Sale	118.41	20,000	2,368,202		Feb 09 04:55 PM
Guindo Chirfi	Chief Marketing Officer	Feb 09 '26	Sale	118.41	10,000	1,184,101	70,615	Feb 09 04:04 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Option Exercise	119.15	121,573	14,485,690	125,708	Feb 09 04:01 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Sale	119.15	121,573	14,485,690	68,916	Feb 09 04:01 PM
RICHARD ROBERT DELUCA JR.	Officer	Feb 06 '26	Proposed Sale	120.92	37,685	4,557,025		Feb 06 04:35 PM
DAVID WILLIAMS	Officer	Feb 06 '26	Proposed Sale	121.91	5,000	609,525		Feb 06 04:33 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Option Exercise	77.62	5,000	388,100	35,838	Feb 06 04:20 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Sale	121.91	5,000	609,525	30,838	Feb 06 04:20 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 06 '26	Proposed Sale	121.87	15,000	1,827,992		Feb 06 04:19 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Option Exercise	62.07	4,000	248,280	14,605	Feb 06 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Sale	119.67	6,400	765,920	8,205	Feb 06 04:18 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 06 '26	Sale	121.87	15,000	1,827,992	21,197	Feb 06 04:15 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Option Exercise	53.06	41,997	2,228,361	132,189	Feb 06 04:13 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Sale	119.61	41,997	5,023,312	90,192	Feb 06 04:13 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Option Exercise	56.04	15,087	845,475	117,357	Feb 06 04:12 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Sale	118.77	15,087	1,791,824	102,270	Feb 06 04:12 PM
Guindo Chirfi	Chief Marketing Officer	Feb 05 '26	Sale	121.88	20,000	2,437,676	80,615	Feb 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Feb 06 '26	Sale	120.92	37,685	4,557,025	160,174	Feb 06 04:08 PM
Davis Robert M	Chairman, CEO & President	Feb 04 '26	Sale	118.04	47,434	5,599,327	443,602	Feb 06 04:05 PM
CHIRFI GUINDO	Officer	Feb 05 '26	Proposed Sale	121.88	20,000	2,437,676		Feb 05 04:25 PM
DALTON SMART	Officer	Feb 04 '26	Proposed Sale	119.67	6,400	765,920		Feb 04 04:38 PM
ROBERT M. DAVIS	Officer	Feb 04 '26	Proposed Sale	118.02	47,434	5,598,137		Feb 04 04:29 PM
DEAN LI	Officer	Feb 04 '26	Proposed Sale	118.77	15,087	1,791,824		Feb 04 04:27 PM
CAROLINE A LITCHFIELD	Officer	Feb 04 '26	Proposed Sale	119.61	41,997	5,023,312		Feb 04 04:26 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Nov 10 '25	Sale	87.00	7,085	616,395	0	Nov 12 04:01 PM
CRISTAL DOWNING	Officer	Nov 10 '25	Proposed Sale	87.00	7,085	616,395		Nov 10 04:07 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Nov 03 '25	Sale	83.59	8,614	720,040	24,578	Nov 04 04:02 PM
DAVID WILLIAMS	Officer	Nov 03 '25	Proposed Sale	83.59	8,614	720,040		Nov 03 04:09 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 04 '25	Option Exercise	79.29	17,119	1,357,366	41,445	Aug 05 08:46 AM
Guindo Chirfi	Chief Marketing Officer	Aug 04 '25	Option Exercise	79.29	36,903	2,926,039	107,409	Aug 05 08:43 AM
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM

Open in Screener

RXRX

Recursion Pharmaceuticals Inc

Feb 13 • 04:00PM ET

3.49

-0.09 -2.51 %

Healthcare • Biotechnology • USA • NASD

RXRX Recursion Pharmaceuticals Inc daily Stock Chart

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK VTI XBI ARKG VB IWM VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.46%	Shs Outstand	485.21M	Perf Week	-12.31%
Market Cap	1.82B	Forward P/E	-	EPS next Y	-1.14	Insider Trans	-1.86%	Shs Float	434.79M	Perf Month	-28.04%
Enterprise Value	1.24B	PEG	-	EPS next Q	-0.30	Inst Own	54.92%	Short Float	38.08%	Perf Quarter	-24.95%
Income	-715.54M	P/S	41.57	EPS this Y	7.30%	Inst Trans	3.61%	Short Ratio	7.32	Perf Half Y	-38.12%
Sales	43.69M	P/B	1.64	EPS next Y	27.38%	ROA	-67.31%	Short Interest	165.55M	Perf YTD	-14.67%
Book/sh	2.13	P/C	2.74	EPS next 5Y	17.77%	ROE	-91.06%	52W High	12.36 -71.76%	Perf Year	-58.94%
Cash/sh	1.27	P/FCF	-	EPS past 3/5Y	-15.58% -35.28%	ROIC	-64.53%	52W Low	3.49 0.00%	Perf 3Y	-56.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	79.47% 90.93%	Gross Margin	-160.40%	Volatility	6.45% 6.67%	Perf 5Y	-
Dividend TTM	-	EV/Sales	28.29	EPS Y/Y TTM	-18.46%	Oper. Margin	-1656.17%	ATR (14)	0.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.60	Sales Y/Y TTM	-32.98%	Profit Margin	-1637.81%	RSI (14)	33.44	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	-7.02%	SMA20	-16.78%	Beta	0.97	Target Price	7.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-80.16%	SMA50	-20.42%	Rel Volume	0.70	Prev Close	3.58
Employees	-	LT Debt/Eq	0.06	Earnings	Nov 05 BMO	SMA200	-29.04%	Avg Volume	22.63M	Price	3.49
IPO	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.53% -70.60%	Trades		Volume	15,943,542	Change	-2.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight	$11
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Feb-12-26 10:00AM	2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off (24/7 Wall St.)
07:59AM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
Feb-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-04-26 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -8.72%
Jan-29-26 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
09:25AM	Loading…
09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
06:15AM	Forget 2025: These 2 Growth Stocks Could Soar in 2026 (Motley Fool)
Jan-28-26 09:21PM	Can This Beaten-Down AI Stock Bounce Back in 2026? (Motley Fool)
Jan-24-26 03:35AM	Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? (Insider Monkey)
Jan-23-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-20-26 10:14AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) -5.78%
Jan-18-26 12:30PM	JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects (Insider Monkey)
Jan-16-26 05:05PM	2 AI Stocks to Buy in 2026, and 1 to Avoid (Motley Fool) -5.78%
Jan-15-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-08-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:20PM	Loading…
Jan-07-26 08:20PM	Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates (Insider Monkey) +6.81%
Jan-06-26 07:59AM	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
09:10AM	JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline (Insider Monkey)
Jan-01-26 07:45AM	Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. (Motley Fool)
Dec-30-25 11:49PM	Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
Dec-29-25 11:42AM	Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP (Insider Monkey)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Dec-28-25 12:46PM	Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform (Insider Monkey)
Dec-24-25 09:00AM	Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? (Barchart)
Dec-21-25 07:40AM	Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? (Insider Monkey)
Dec-19-25 07:33AM	Cathie Wood Keeps Dumping Tesla Stock -- Here is Why (GuruFocus.com)
Dec-18-25 05:24AM	Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet (Insider Monkey) -5.13%
Dec-17-25 05:27PM	Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday (Motley Fool) +11.43%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
05:30PM	Loading…
Dec-08-25 05:30PM	Why Recursion Pharamaceuticals Topped the Market Today (Motley Fool)
07:30AM	Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks (GlobeNewswire)
12:32AM	Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" (Insider Monkey)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:04PM	Lightning Round: Recursion Pharmaceuticals and NuScale Power (CNBC TV) +5.58%
06:05AM	10 AI Stocks Worth Buying Right Now (Motley Fool)
Dec-01-25 08:30AM	Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 (GlobeNewswire) -5.83%
Nov-28-25 06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-24-25 08:53AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Nov-22-25 10:11AM	Recursion (RXRX) Jumps 8% on Bargain-Hunting (Insider Monkey)
Nov-21-25 05:02AM	Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? (Insider Monkey) +8.31%
Nov-19-25 08:13AM	Is Recursion Pharmaceuticals a Meme Stock? (Motley Fool)
Nov-12-25 09:45AM	Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock (Motley Fool)
Nov-06-25 09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks) -6.85%
Nov-05-25 07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:34AM	Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:28AM	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth (GlobeNewswire)
Nov-04-25 08:45AM	3 Things Investors Need to Know About Recursion Pharmaceuticals (Motley Fool) -8.09%
08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-31-25 06:15AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Oct-29-25 10:00AM	Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks) -6.19%
08:00AM	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th (GlobeNewswire)
Oct-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.89%
08:56AM	Jim Cramer on Recursion Pharmaceuticals: "Now, It's a Meme Stock" (Insider Monkey)
Oct-21-25 12:56PM	Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings (Insider Monkey) -8.53%
10:00AM	Up 25% in 1 Month, Is This Stock a Buy? (Motley Fool)
Oct-19-25 04:00AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Oct-16-25 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -6.33% -7.86%
10:30AM	Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event (Insider Monkey)
09:31AM	Is Recursion Pharmaceuticals a Millionaire Maker? (Motley Fool)
Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 05:00AM	Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference (Insider Monkey)
Oct-08-25 11:22AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) +16.44%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
Oct-07-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.42%
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-30-25 02:49PM	Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) (Insider Monkey)
Sep-29-25 09:02AM	Nvidia Has Invested in These 6 Companies. Should You Follow Suit? (Motley Fool)
01:22AM	Jim Cramer on Recursion: "I Need to See a Proof of Concept Here" (Insider Monkey)
Sep-28-25 10:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
09:32AM	The Biotech Stock That's Too Risky for Most Investors (Motley Fool)
07:00AM	Nvidias $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidias cash being recycled? (Fortune)
Sep-27-25 06:45AM	10 Hidden-Gem AI Stocks to Buy Right Now (Motley Fool)
Sep-26-25 04:42AM	Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now (Motley Fool)
Sep-25-25 09:15AM	Looking for the Next Big Pop? Heres Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce (Barchart) -5.12%
Sep-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
Sep-21-25 09:26AM	Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances (Insider Monkey)
Sep-15-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:17AM	Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 (Insider Monkey)
04:44AM	Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. (Motley Fool)
Sep-03-25 06:00AM	When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts (Motley Fool)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:45AM	3 AI Stocks Disrupting Trillion-Dollar Industries (Motley Fool)
Aug-29-25 08:30AM	If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-28-25 05:05AM	Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:45AM	1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell (Motley Fool)
Aug-24-25 12:53AM	Needham Maintains Buy Rating on Recursion (RXRX) (Insider Monkey)
Aug-23-25 04:00AM	The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode (Motley Fool)
Aug-22-25 05:53PM	Why Recursion Pharmaceuticals Stock Caught a Cold This Week (Motley Fool)
Aug-21-25 10:45AM	Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-17-25 06:16PM	Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid (Insider Monkey)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.36%
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Director	Feb 04 '26	Sale	4.12	40,000	164,800	913,839	Feb 06 05:53 PM
Borgeson Blake	Director	Feb 03 '26	Sale	4.20	220,000	924,000	6,429,863	Feb 06 05:53 PM
Gibson Christopher	Director	Feb 04 '26	Proposed Sale	4.12	40,000	164,800		Feb 04 09:50 AM
Borgeson Blake	Director	Feb 03 '26	Proposed Sale	4.20	220,000	924,000		Feb 03 11:26 AM
Gibson Christopher	Director	Jan 20 '26	Sale	4.47	40,000	178,800	913,839	Jan 22 07:34 PM
Gibson Christopher	Director	Jan 20 '26	Proposed Sale	4.47	40,000	178,800		Jan 20 11:26 AM
Borgeson Blake	Director	Jan 06 '26	Sale	4.36	220,000	959,200	6,649,863	Jan 08 05:01 PM
Gibson Christopher	Director	Jan 05 '26	Sale	4.25	40,000	170,000	933,839	Jan 07 05:04 PM
Borgeson Blake	Director	Jan 06 '26	Proposed Sale	4.36	220,000	959,200		Jan 06 09:40 AM
Gibson Christopher	Director	Jan 05 '26	Proposed Sale	4.25	40,000	170,000		Jan 05 11:07 AM
Taylor Ben R	Chief Financial Officer	Dec 29 '25	Sale	4.18	21,383	89,381	761,550	Dec 30 07:35 PM
Khan Najat	Chief R&D Commercial Officer	Dec 22 '25	Sale	4.41	124,403	548,592	611,135	Dec 29 05:24 PM
Taylor Ben R	Officer	Dec 29 '25	Proposed Sale	4.18	21,383	89,381		Dec 29 09:41 AM
Najat Khan	Officer	Dec 22 '25	Proposed Sale	4.41	124,403	548,588		Dec 22 12:20 PM
Gibson Christopher	Chief Executive Officer	Dec 19 '25	Sale	4.50	40,000	180,000	913,839	Dec 19 05:04 PM
Gibson Christopher	Officer	Dec 19 '25	Proposed Sale	4.50	40,000	180,000		Dec 19 09:52 AM
Gibson Christopher	Chief Executive Officer	Dec 04 '25	Sale	4.63	40,000	185,200	933,839	Dec 05 07:20 PM
Borgeson Blake	Director	Dec 02 '25	Sale	4.37	220,000	961,400	6,869,863	Dec 04 04:51 PM
Gibson Christopher	Officer	Dec 04 '25	Proposed Sale	4.63	40,000	185,200		Dec 04 10:01 AM
Borgeson Blake	Director	Dec 02 '25	Proposed Sale	4.37	220,000	961,400		Dec 02 12:15 PM
Gibson Christopher	Chief Executive Officer	Nov 19 '25	Sale	4.16	40,000	166,400	913,839	Nov 19 07:37 PM
Gibson Christopher	Officer	Nov 19 '25	Proposed Sale	4.16	40,000	166,400		Nov 19 10:17 AM
Gibson Christopher	Chief Executive Officer	Nov 04 '25	Sale	5.21	40,000	208,400	974,229	Nov 06 04:23 PM
Gibson Christopher	Officer	Nov 04 '25	Proposed Sale	5.21	40,000	208,400		Nov 04 09:51 AM
Gibson Christopher	Chief Executive Officer	Oct 23 '25	Sale	5.70	100,000	570,000	954,229	Oct 24 06:49 PM
Gibson Christopher	Officer	Oct 23 '25	Proposed Sale	5.70	100,000	570,000		Oct 23 10:37 AM
Gibson Christopher	Chief Executive Officer	Oct 10 '25	Sale	6.04	100,000	604,000	974,229	Oct 10 06:03 PM
Gibson Christopher	Officer	Oct 10 '25	Proposed Sale	6.04	100,000	604,000		Oct 10 10:24 AM
Gibson Christopher	Chief Executive Officer	Sep 25 '25	Sale	4.76	100,000	476,000	954,229	Sep 26 06:32 PM
Gibson Christopher	Officer	Sep 25 '25	Proposed Sale	4.76	100,000	476,000		Sep 25 09:49 AM
Gibson Christopher	Chief Executive Officer	Sep 10 '25	Sale	4.71	100,000	471,000	974,229	Sep 12 04:24 PM
Gibson Christopher	Officer	Sep 10 '25	Proposed Sale	4.71	100,000	471,000		Sep 10 11:10 AM
Gibson Christopher	Chief Executive Officer	Aug 26 '25	Sale	4.84	100,000	484,000	954,229	Aug 28 08:00 PM
Gibson Christopher	Officer	Aug 26 '25	Proposed Sale	4.84	100,000	484,000		Aug 26 10:03 AM
Khan Najat	Chief R&D Commercial Officer	Aug 18 '25	Sale	5.52	36,599	202,173	668,197	Aug 19 06:22 PM
Khan Najat	Officer	Aug 18 '25	Proposed Sale	5.52	36,599	202,169		Aug 18 03:18 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	500,300	2,641,584	1,004,619	Aug 13 09:03 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	117,875	622,380	0	Aug 13 09:03 PM
Gibson Christopher	Officer	Aug 11 '25	Proposed Sale	5.28	617,875	3,262,380		Aug 11 03:31 PM
Gibson Christopher	Chief Executive Officer	Mar 27 '25	Sale	6.04	138,574	836,987	1,117,450	Mar 28 04:52 PM
Gibson Christopher	Officer	Mar 27 '25	Proposed Sale	6.04	138,574	836,987		Mar 27 12:02 PM
Gibson Christopher	Chief Executive Officer	Mar 05 '25	Sale	6.58	20,000	131,600	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '25	Sale	6.37	20,000	127,400	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Officer	Mar 06 '25	Proposed Sale	6.37	20,000	127,400		Mar 06 11:55 AM
Gibson Christopher	Officer	Mar 05 '25	Proposed Sale	6.58	20,000	131,600		Mar 05 10:13 AM

MRK

Merck & Co Inc

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience